Clinical phase III comparative study on garenoxacin versus levofloxacin in patients with bacterial pneumonia

Japanese Journal of Chemotherapy

Volumn 55, Issue SUPPL. 1, 2007, Pages 127-143

  Kobayashi, Hiroyuki ^a   Watanabe, Akira ^b   Aoki, Nobuki ^c   Odagiri, Shigeki ^d   Kawai, Shin ^a   Niki, Yoshihito ^e,h   Kohno, Shigeru ^f,i   Saito, Atsushi ^g,j  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c Shinrakuen Hospital   (Japan)

^d Odagiri Respiratory Disease Clinic   (Japan)

^e KAWASAKI MEDICAL SCHOOL   (Japan)

^f NAGASAKI UNIVERSITY   (Japan)

^g UNIVERSITY OF THE RYUKYUS   (Japan)

^h SHOWA UNIVERSITY   (Japan)

ⁱ NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^j JAPANESE RED CROSS SOCIETY   (Japan)

more..

Author keywords

Double blind study; Garenoxacin; Levofloxacin; Pneumonia

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM DERIVATIVE; GARENOXACIN; LEVOFLOXACIN; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

ABDOMINAL PAIN; ABNORMAL SENSATION; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANOREXIA; ARTICLE; BACTERIAL PNEUMONIA; BLOOD PRESSURE; CHEILITIS; CHEMICAL STRUCTURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ECZEMA; EOSINOPHIL COUNT; EPIGASTRIC PAIN; ERYTHEMA; FEMALE; GLOSSITIS; HEADACHE; HEMOPTYSIS; HUMAN; INCIDENCE; INFECTION CONTROL; INSOMNIA; LABORATORY TEST; LACTATE BLOOD LEVEL; LEUKOCYTE COUNT; LOOSE FECES; MALE; NEUTROPHIL COUNT; NIGHT SWEAT; NIGHTMARE; NOSE IRRITATION; PAPULAR RASH; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRURITUS; RASH; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; THIRST; THORAX PAIN; THROMBOCYTE COUNT; TONGUE DISEASE; TREATMENT OUTCOME; VOMITING;

EID: 35348948599     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Hayashi K, Takahata M, Kawamura Y, Todo Y: Synthesis, antibacterial activity, and toxicity of 7-(isoindolin-5-yl)-4-oxoquinoline-3-carboxylic acids. Discovery of the novel des-F (6)-quinolone antibacterial agent garenoxacin (T-3811 or BMS-284756). Arzneimittelforschung 2002; 52: 903-13
2. Takahata M, Mitsuyama J, Yamashiro Y, Yonezawa M, Araki H, Todo Y, et al: In vitro and in vivo antimicrobial activities of T-3811 ME, a novel des-F (6)-quinolone. Antimicrob Agents Chemother 1999; 43: 1077-84
3. Fung-Tomc J C, Minassian B, Kolek B, Huczko E, Aleksunes L, Stickle T, et al: Antibacterial spectrum of a novel des-fluoro (6) quinolone, BMS-284756. Antimicrob Agents Chemother 2000; 44: 3351-6
4. Morosini M I, Loza E, del Campo R, Almaraz F, Baquero F, Canton R: Fluoroquinolone-resistant Streptococcus pneumoniae in Spain: Activities of garenoxacin against clinical isolates including strains with altered topoisomerases. Antimicrob Agents Chemother 2003; 47: 2692-5
5. Zhao X, Eisner W, Perl-Rosenthal N, Kreiswirth B, Drilica K: Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 1023-7
6. Gaijar D A, Bello A, Ge Z, Christopher L, Grasela D M: Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob Agents Chemother 2003; 47: 2256-63
7. Forrest A, Nix D E, Ballow C H, Goss T F, Birmingham M C, Schentag J J: Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-81
8. Japanese source.
9. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Test; M100-S15. CLSI, 2005
10. Japanese source.
11. Japanese source.